A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation (NCT03900429)
MAESTRO-NASH
This trial is No longer recruiting
Registration number NCT03900429
Program & service
This trial is being run with the Specialty Medicine service, and as part of the Gastroenterology program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor Stuart Roberts
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR